EFG Asset Management (Americas)’s Alnylam Pharmaceuticals ALNY Stock Holding History

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	$4.44M	Sell	9,738 -1,877	-16%	-$764K	0.77%	42
2025 Q2	$3.79M	Sell	11,615 -1,757	-13%	-$486K	0.7%	46
2025 Q1	$3.61M	Sell	13,372 -1,574	-11%	-$405K	0.73%	46
2024 Q4	$3.52M	Sell	14,946 -7	-0%	-$1.84K	0.68%	51
2024 Q3	$4.11M	Sell	14,953 -2,039	-12%	-$531K	0.8%	43
2024 Q2	$4.13M	Buy	16,992 +6,106	+56%	+$964K	0.81%	42
2024 Q1	$1.63M	Sell	10,886 -5,365	-33%	-$895K	0.5%	61
2023 Q4	$3.11M	Buy	16,251 +794	+5%	+$135K	0.67%	46
2023 Q3	$2.74M	Sell	15,457 -278	-2%	-$53K	0.66%	49
2023 Q2	$2.99M	Buy	15,735 +556	+4%	+$110K	0.69%	45
2023 Q1	$3.04M	Sell	15,179 -238	-2%	-$50K	0.73%	45
2022 Q4	$3.66M	Buy	15,417 +275	+2%	+$58.7K	0.91%	35
2022 Q3	$3.03M	Buy	15,142 +1,893	+14%	+$361K	0.77%	44
2022 Q2	$1.93M	Sell	13,249 -3,489	-21%	-$495K	0.46%	59
2022 Q1	$2.73M	Buy	+16,738	New	+$2.55M	0.51%	55
2021 Q3	–	Sell	-26,187	Closed	-$4.44M	–	136
2021 Q2	$4.44M	Buy	26,187 +1,747	+7%	+$256K	0.82%	44
2021 Q1	$3.45M	Buy	24,440 +1,020	+4%	+$153K	0.71%	52
2020 Q4	$3.04M	Buy	23,420 +2,341	+11%	+$313K	0.62%	58
2020 Q3	$3.07M	Buy	+21,079	New	+$3M	0.69%	57